CancerNCT04382495
The Impact of COVID-19 Pandemic on Cancer Care
An observational study of Cancer, run by El Zaitoun Specialized Hospital at 1 site in Egypt.
Trial summary
The situation of COVID-19 pandemic creates many challenges for cancer patients and caregivers. Some modifications in cancer management have been evolved from cancer societies and organizations to support oncology professionals as much as possible to deliver optimal care to their cancer patients in such exceptional… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer
- What is being tested?
- survey
- How many people
- 300 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Jun 2020to 30 Jan 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: the study survey will be distributed through social media to cancer patients and survivors in Egypt. We plan to enroll as many participants as possible without limitation of the number although we hope to achieve at least 400 participants.
Who may be able to join
- cancer patients or survivors in Egypt.
Who cannot join
- No exclusion criteria
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Impact of COVID-19 Pandemic on Cancer Care Provision: a Cross-sectional Study of Egyptian Patients' Perspectives and Concerns
The situation of COVID-19 pandemic creates many challenges for cancer patients and caregivers. Some modifications in cancer management have been evolved from cancer societies and organizations to support oncology professionals as much as possible to deliver optimal care to their cancer patients in such exceptional circumstances, and to protect patients from infection with COVID-19 as much as possible.
Read the detailed description
In oncology practice during this pandemic, many cancer patients still feeling uncertainty about their cancer management and treatment outcome . The study is aiming to better understand the impact of the COVID-19 pandemic on cancer care from patients' and survivors' perspective.
- Conditions
- Cancer
- Being tested
- survey
- Keywords
- Cancer Care, COVID-19
- Medical subject headings
- Neoplasms, COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
surveyOther
online survey
What is being measured
The primary outcome is the main question the study is designed to answer.
patients' and survivors' perspective of their cancer care during COVID-19 pandemic
measured by online survey to understand the impact of COVID-19 pandemic on cancer care
Measured: one month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2020
- Study start15 Jun 2020
- Primary completion1 Dec 2021
- Study completion30 Jan 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 300 participants (actual)
Sponsor and investigators
- Lead sponsor
- El Zaitoun Specialized Hospital
- Sponsor type
- Other government
- Collaborators
- Ain Shams University
- Responsible party
- Principal investigator, Aalaa Abdou, El Zaitoun Specialized Hospital
- Investigators
- Ahmed Abdelaziz, MD, Study director, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04382495
- Sponsor's protocol ID
- Cancer Care during Covid-19
- Status last verified
- Aug 2024
- First submitted
- 8 May 2020
- Last updated
- 28 Aug 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: email
Study at a glance
From the registry record, last updated by the sponsor on 28 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of COVID-19 Pandemic on Cancer Care Provision: a Cross-sectional Study of Egyptian Patients' Perspectives and Concerns
- ClinicalTrials.gov ID
- NCT04382495
- Acronym / sponsor ID
- Cancer Care during Covid-19
- Conditions
- Cancer
- Keywords
- Cancer Care, COVID-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 300 participants (actual)
- Lead sponsor
- El Zaitoun Specialized HospitalOther government
- Collaborators
- Ain Shams University
- Study start
- 15 Jun 2020 (actual)
- Primary completion
- 1 Dec 2021 (actual)
- Study completion
- 30 Jan 2022 (actual)
- First posted
- 11 May 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The situation of COVID-19 pandemic creates many challenges for cancer patients and caregivers. Some modifications in cancer management have been evolved from cancer societies and organizations to support oncology professionals as much as possible to deliver optimal care to their cancer patients in such exceptional circumstances, and to protect patients from infection with COVID-19 as much as possible.
Detailed description
In oncology practice during this pandemic, many cancer patients still feeling uncertainty about their cancer management and treatment outcome . The study is aiming to better understand the impact of the COVID-19 pandemic on cancer care from patients' and survivors' perspective.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- the study survey will be distributed through social media to cancer patients and survivors in Egypt. We plan to enroll as many participants as possible without limitation of the number although we hope to achieve at least 400 participants.
Key inclusion criteria (1 listed)
- cancer patients or survivors in Egypt.
Key exclusion criteria (1 listed)
- No exclusion criteria
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| surveyonline survey | Other | – |
Primary outcome
patients' and survivors' perspective of their cancer care during COVID-19 pandemic
Time frame: one month
measured by online survey to understand the impact of COVID-19 pandemic on cancer care
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Aug 2024.
- Individual participant dataSharing planned: Undecided. email
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed Abdelaziz, MD study director
Ain Shams University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, run by El Zaitoun Specialized Hospital at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
patients' and survivors' perspective of their cancer care during COVID-19 pandemic (time frame: one month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2024.